Introduction; Rectal cancer is the third leading cancer in the world in terms of incidence and mortality according to GLOBOCCAN. The prognosis of the disease varies according to the stage, being better in the early stages and worse in the advanced and metastatic stages. Early diagnosis of colorectal cancer made through screening programs is accompanied by an improvement in cancer progression. The introduction of colonoscopy examinations and testing for blood clots has made it possible to

more »

... e precancerous lesions and colorectal cancer in the early stages when the survival rate is better [1]. The treatment of colorectal cancer has evolved from just surgery before the 1980s to chemotherapy and radiotherapy in the 1980s and improved in later years with the introduction of new cytotoxic drugs that have improved survival. [2]. With advances in molecular biology methods, it is the possible introduction as part of the treatment of new targeting and immunomodulatory drugs based on the results of these molecular tests. Treatment with these drugs has brought an improvement in the course of the disease of patients with colorectal cancer. [3]. Conclusion; The strategy for treatment for CRC should be assessed with respect to its effectiveness, sensitivity, the number of false positive results, safety, and comfort. Furthermore, the cost and economic factors pertaining to the screening programs should be observed in order to help patients with decision-making, and the prevailing clinical policies should be taken into consideration.